TheEdgeResearch
Home / Stocks / ONPH

Oncology Pharma Inc. (ONPH)

OTC Healthcare Biotechnology
$0.05 ▼ -24.64%
Market Cap
$1.4M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.13
52-Wk Range
0.0001-0.364
CEO
George Malesek
Country
US
Currency
USD

Oncology Pharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Francisco, CA, US. The stock last traded at $0.05, down 24.64% on the session, giving a market capitalisation of $1.4M. On trailing twelve-month figures it carries a trailing P/E of 520.00, a net margin of 0.0%. Its beta of -0.13 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
520.00
Price / Sales
0.00
Price / Book
3.43
EV / EBITDA
-357.78
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
0.53
Current ratio
0.00
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
1994-10-31
Headquarters
San Francisco, CA, US
About Oncology Pharma Inc.

Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents. The company has a collaborative and licensing agreement with Kalos Therapeutics Inc. to explore treatment possibilities for the COVID-19 virus. Originally incorporated in 1993, the company was known as SourcingLink.net Inc. until it rebranded as Oncology Pharma Inc. in June 2019. Its operations are based in San Francisco, California.

Comparable companies

Oncology Pharma Inc. is most often compared with the following Healthcare names:

AMPEARNIBTTXBXRXQCALAINNDIVBTPANCTLOGWUHN
More research on ONPH
ONPH technical analysis ONPH TheEdge Score Compare against peers
Open full interactive analysis & DCF →